



Joint BioRN & Ci3 Annual Conference 2018

# Immunotherapy and beyond - The next generation of cancer treatment

October 25<sup>th</sup>, 2018 hosted by Merck in Darmstadt



## - AGENDA -

**Moderation:** André Domin, Technology Park Heidelberg

08:30 – 09:15 REGISTRATION AND GET-TOGETHER

09:15 – 10:05 WELCOME AND INTRODUCTION

09:15 – 09:30 **Welcome from the Organizers**  
Gitte Neubauer, BioRN & Christoph Huber, Ci3

09:30 – 09:35 **Welcome from the Host**  
Ulrich Betz, Merck

09:35 – 09:50 **Rethinking the Pharma Model**  
Luciano Rossetti, Merck

09:50 – 10:05 **Health Axis Europe Partnering –  
A Joint Project for Tailored Innovation Scouting**  
Julia Schaft, BioRN

10:05 – 10:55 THERAPEUTIC VACCINATION

10:05 – 10:35 **KEYNOTE: Individualized Cancer Immunotherapy**  
Ugur Sahin, BioNTech/TRON

10:35 – 10:55 **Tumor Antigen-Loaded Natural Dendritic Cells:  
A More Powerful Next Generation Cancer Vaccine?**  
Gerty Schreibelt, Radboudumc

10:55 – 11:25 COFFEE BREAK & POSTER SESSION

<b>11:25 – 12:25</b>	<b>CELLULAR THERAPIES</b>
11:25 – 11:45	<b>Challenges in CAR-T Manufacturing</b> Andrea Schilz, BioNTech IMFS
11:45 – 12:05	<b>CAR-Engineered NK Cells: Off-the-Shelf Therapeutics Bridging Innate and Adaptive Immunity</b> Winfried Wels, Georg-Speyer-Haus
12:05 – 12:25	<b>Receptor-Targeted Viral Vectors in Immunotherapy</b> Christian Buchholz, Paul-Ehrlich-Institut
<b>12:25 – 13:25</b>	<b>COMBINATION THERAPIES</b>
12:25 – 12:45	<b>Combinations and/or Bi-Functional Molecules as Next Generation IO Therapies</b> Jörn-Peter Halle, Merck
12:45 – 13:05	<b>Intelligent Combination Treatment</b> Dirk Jäger, National Center for Tumor Diseases
13:05 – 13:25	<b>Therapeutic Strategies Based on Innate Immunity and Affimed's ROCK® Platform</b> Martin Treder, Affimed
<b>13:25 – 14:55</b>	<b>LUNCH BREAK &amp; POSTER SESSION</b>
<b>14:55 – 16:05</b>	<b>NOVEL TARGETS AND AGENTS</b>
14:55 – 15:15	<b>Apogenix' TNFR-Mediated Signaling Modulators – Innovative Immuno-Oncology Therapeutics</b> Thomas Höger, Apogenix
15:15 – 15:35	<b>Development of First-In-Class Immuno-Oncology Drugs in the Context of the DKFZ-Bayer Alliance</b> Rienk Offringa, German Cancer Research Center
15:35 – 16:05	<b>KEYNOTE: Future Innovation in Cancer Therapeutics – An AbbVie Oncology Perspective</b> Neil Gallagher, AbbVie
<b>16:05 – 16:30</b>	<b>WRAP-UP</b>
16:05 – 16:30	<b>Wrap-Up and Closing Remarks</b> Michael Boutros, BioRN, Özlem Türeci, Ci3 & Ulrich Betz, Merck
<b>16:30 – 17:30</b>	<b>GET-TOGETHER &amp; POSTER SESSION</b>